Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.82 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.70 |
| ▸ | PCSK9 | Q8NBP7 | 7/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523332 | 0.90 | AHR (1.00) | AHRGPR84PCSK9HTR1AMAPT | |
| SCHEMBL17523175 | 0.82 | PCSK9 (0.71) | AHRGPR84PCSK9LOXL2 | |
| SCHEMBL29886525 | 0.82 | AHR (1.00) | AHRGPR84PCSK9LOXL2MEN1 | |
| SCHEMBL12852216 | 0.82 | AHR (1.00) | AHRGPR84PCSK9LOXL2MEN1 | |
| SCHEMBL6995767 | 0.81 | AHR (0.67) | AHRLOXL2MEN1KMT2AMAPT | |
| SCHEMBL867547 | 0.79 | LOXL2 (0.75) | AHRLOXL2MEN1KMT2AMAPT | |
| SCHEMBL20143884 | 0.79 | AHR (0.71) | AHRGPR84PCSK9MEN1KMT2A | |
| SCHEMBL10443687 | 0.77 | LOXL2 (0.63) | AHRLOXL2MEN1KMT2AMAPT | |
| SCHEMBL20143867 | 0.76 | AHR (0.59) | AHRGPR84PCSK9MEN1KMT2A | |
| SCHEMBL3090779 | 0.76 | GPR84 (0.71) | AHRGPR84MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730833-B2 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180222861-A1 | SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-08-09 | — | — | US | disclosed |
| US-9969686-B2 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730833-B2 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | GLP1R, GIPR, INSR | AHR 23/4885GPR84 413/4885PCSK9 5/4885 |
| US-20180222861-A1 | SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLP1R, GIPR, INSR | AHR 23/4885GPR84 413/4885PCSK9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.